This post was originally published on News-medical.net
You will shortly be re-directed to the publisher's website
A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising immune responses and improved recurrence-free survival in high-risk triple-negative breast cancer patients.